The Nose-Lung Connection Isn't a Coincidence
Doctors have long noticed that people with severe nasal polyps often have asthma, too. For a long time, these were treated as separate problems — an ENT handles the nose, a pulmonologist handles the lungs. But a growing body of research supports what's called the "global airway" hypothesis: the upper airway (your nose and sinuses) and the lower airway (your windpipe and lungs) are part of the same system. Inflammation in one place doesn't stay there.
The root cause in many people with nasal polyps is an overactive immune signal called IL-5. This molecule recruits a type of white blood cell called an eosinophil, sending it flooding into tissues where it doesn't belong. In the nose, eosinophils build up and form polyps. In the lungs, they tighten airways and trigger asthma attacks. The body, in a sense, is attacking itself in two places at once.
What the Study Looked At
A randomized controlled trial published in the International Forum of Allergy & Rhinology enrolled 58 patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) — a mouthful of a diagnosis that simply means: chronic, serious nasal polyp disease. Many of these patients also had asthma.
Researchers split participants into two groups:
- Group 1: Mepolizumab alone (a drug that blocks IL-5)
- Group 2: Mepolizumab combined with FESS (functional endoscopic sinus surgery)
They tracked outcomes at the start of the study, at 6 months, and at 12 months. They measured inflammation markers in the blood and nasal tissue, lung function tests, and how patients felt day-to-day.
What Is Mepolizumab, Exactly?
Mepolizumab is a biologic medication — meaning it's an engineered antibody, not a traditional chemical drug. It's given as an injection, typically once a month. Its job is specific: block IL-5, the immune signal that sends eosinophils into overdrive. By cutting off that signal, the drug reduces inflammation throughout the whole airway system — nose and lungs together.
What Is FESS?
FESS stands for functional endoscopic sinus surgery. It sounds intimidating, but it's a minimally invasive procedure done entirely through the nostrils using a tiny camera. The surgeon opens up the drainage passages of the sinuses and removes polyps directly. There are no external cuts. Recovery typically takes a couple of weeks. The goal is to restore normal sinus drainage and remove the physical obstruction.
Both groups improved significantly — and that itself is important news for patients who've felt stuck with this condition.
Lung function improved in both groups. A key measurement called FEV1 (how much air you can force out of your lungs in one second) increased meaningfully in both the drug-only group and the surgery-plus-drug group. FVC, another lung function measure, also improved. These weren't small statistical blips — the improvements were statistically significant and clinically meaningful.
Inflammation came down across the board. Blood eosinophil counts fell. A marker called FeNO — exhaled nitric oxide, a sign of airway inflammation — improved. Even the eosinophils inside nasal polyp tissue decreased.
All patients reported feeling better. Nasal congestion, overall symptom burden, quality of life — all improved in both groups.
But there was a difference. The group that received both the drug and surgery saw greater improvements in nose-specific outcomes — things like nasal polyp size, congestion, and overall sinus symptom scores. Surgery added something real for the nose.
What surgery did NOT do was improve lung function further. The drug alone was just as good for the lungs as the drug plus surgery.
Why That Distinction Matters for You
That finding has real practical weight. FESS is not free. It requires anesthesia, recovery time, and carries real (if small) surgical risks. Insurance coverage varies. Not everyone wants an operation.
This study suggests you may be able to ask your doctor a sharper question: What's bothering me most?
- If your main struggle is nasal congestion, loss of smell, blocked sinuses, and recurring sinus infections — adding surgery to the biologic may be worth it for you.
- If your main concern is asthma control, wheezing, or breathing difficulty — the drug alone may give you most of what you need without surgery.
That's not a one-size-fits-all answer, but it's a more honest map.
This study is promising but not definitive. Only 58 patients were enrolled — a small number for drawing broad conclusions. The follow-up period was 12 months, which is long enough to see early effects but not long enough to know how things look at 3 or 5 years. Whether polyps come back, whether asthma control holds, and whether these benefits are durable are all still open questions. Larger, longer trials are needed.
The Bigger Takeaway
For years, nasal polyps and asthma were siloed into separate clinics with separate specialists. This study adds to a growing pile of evidence that treating the whole airway — not just one end of it — gets better results. A drug that targets the root cause of inflammation systemically can benefit both the nose and the lungs. Surgery, layered on top, can push nasal outcomes even further.
If you or someone you love has been living with severe nasal polyps, especially with asthma, it may be worth asking a specialist about biologics like mepolizumab and what a combined treatment approach might look like for your specific situation.
Would you choose surgery if it only helped your nose — or would you hold off if the medication was already helping your lungs?
Related Reading
- What Are Nasal Polyps and Why Do They Keep Coming Back?
- Biologic Medications for Asthma: How They Work and Who They Help
- The Global Airway: Why Your ENT and Pulmonologist Should Be Talking